Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Journal
Age
Showing 1 to 12 of 109453 entries
Sorted by: Best Match Show Resources per page
Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs

Foster RH, Goa KL.
PMID: 23338224
CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

SYNOPSIS: Paroxetine is the first selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) to be approved for the treatment of patients with panic disorder with or without agoraphobia. It is a highly selective inhibitor of presynaptic serotonin reuptake and does...

Cite
Foster RH, Goa KL. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs. 1997;8(2):163-88doi: 10.2165/00023210-199708020-00010.
Foster, R. H., & Goa, K. L. (1997). Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS drugs, 8(2), 163-88. https://doi.org/10.2165/00023210-199708020-00010
Foster, R H, and Goa, K L. "Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder." CNS drugs vol. 8,2 (1997): 163-88. doi: https://doi.org/10.2165/00023210-199708020-00010
Foster RH, Goa KL. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010. PMID: 23338224.
Copy Download .nbib Format: NLM
Bariatric surgery: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074460
Ont Health Technol Assess Ser. 2005;5(1):1-148. Epub 2005 Jan 01.

OBJECTIVE: To conduct an evidence-based analysis of the effectiveness and cost-effectiveness of bariatric surgery.BACKGROUND: Obesity is defined as a body mass index (BMI) of at last 30 kg/m(2).() Morbid obesity is defined as a BMI of at least 40...

Cite
Bariatric surgery: an evidence-based analysis. Ont Health Technol Assess Ser. 2005;5(1):1-148
(2005). Bariatric surgery: an evidence-based analysis. Ontario health technology assessment series, 5(1), 1-148.
"Bariatric surgery: an evidence-based analysis." Ontario health technology assessment series vol. 5,1 (2005): 1-148.
Bariatric surgery: an evidence-based analysis. Ont Health Technol Assess Ser. 2005;5(1):1-148. Epub 2005 Jan 01. PMID: 23074460; PMCID: PMC3382415.
Copy Download .nbib Format: NLM
Interventions to improve return to work in depressed people.

The Cochrane database of systematic reviews

Nieuwenhuijsen K, Verbeek JH, Neumeyer-Gromen A, Verhoeven AC, Bültmann U, Faber B.
PMID: 33052607
Cochrane Database Syst Rev. 2020 Oct 13;10:CD006237. doi: 10.1002/14651858.CD006237.pub4.

BACKGROUND: Work disability such as sickness absence is common in people with depression.OBJECTIVES: To evaluate the effectiveness of interventions aimed at reducing work disability in employees with depressive disorders.SEARCH METHODS: We searched CENTRAL (The Cochrane Library), MEDLINE, Embase, CINAHL,...

Cite
Nieuwenhuijsen K, Verbeek JH, Neumeyer-Gromen A, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev. 2020;10:CD006237doi: 10.1002/14651858.CD006237.pub4.
Nieuwenhuijsen, K., Verbeek, J. H., Neumeyer-Gromen, A., Verhoeven, A. C., Bültmann, U., & Faber, B. (2020). Interventions to improve return to work in depressed people. The Cochrane database of systematic reviews, 10CD006237. https://doi.org/10.1002/14651858.CD006237.pub4
Nieuwenhuijsen, Karen, et al. "Interventions to improve return to work in depressed people." The Cochrane database of systematic reviews vol. 10 (2020): CD006237. doi: https://doi.org/10.1002/14651858.CD006237.pub4
Nieuwenhuijsen K, Verbeek JH, Neumeyer-Gromen A, Verhoeven AC, Bültmann U, Faber B. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev. 2020 Oct 13;10:CD006237. doi: 10.1002/14651858.CD006237.pub4. PMID: 33052607; PMCID: PMC8094165.
Copy Download .nbib Format: NLM
Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

CNS drugs

Davis R, Wilde MI.
PMID: 26071050
CNS Drugs. 1996 May;5(5):389-402. doi: 10.2165/00023210-199605050-00007.

SYNOPSIS: Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors because mirtazapine...

Cite
Davis R, Wilde MI. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression. CNS Drugs. 1996;5(5):389-402doi: 10.2165/00023210-199605050-00007.
Davis, R., & Wilde, M. I. (1996). Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression. CNS drugs, 5(5), 389-402. https://doi.org/10.2165/00023210-199605050-00007
Davis, R, and Wilde, M I. "Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression." CNS drugs vol. 5,5 (1996): 389-402. doi: https://doi.org/10.2165/00023210-199605050-00007
Davis R, Wilde MI. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression. CNS Drugs. 1996 May;5(5):389-402. doi: 10.2165/00023210-199605050-00007. PMID: 26071050.
Copy Download .nbib Format: NLM
Vortioxetine for depression in adults.

The Cochrane database of systematic reviews

Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C.
PMID: 28677828
Cochrane Database Syst Rev. 2017 Jul 05;7:CD011520. doi: 10.1002/14651858.CD011520.pub2.

BACKGROUND: Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non-pharmacological treatment options,...

Cite
Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. Cochrane Database Syst Rev. 2017;7:CD011520doi: 10.1002/14651858.CD011520.pub2.
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017). Vortioxetine for depression in adults. The Cochrane database of systematic reviews, 7CD011520. https://doi.org/10.1002/14651858.CD011520.pub2
Koesters, Markus, et al. "Vortioxetine for depression in adults." The Cochrane database of systematic reviews vol. 7 (2017): CD011520. doi: https://doi.org/10.1002/14651858.CD011520.pub2
Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev. 2017 Jul 05;7:CD011520. doi: 10.1002/14651858.CD011520.pub2. PMID: 28677828; PMCID: PMC6483322.
Copy Download .nbib Format: NLM
Antidepressants versus placebo for panic disorder in adults.

The Cochrane database of systematic reviews

Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, Turrini G, Furukawa TA, Barbui C.
PMID: 29620793
Cochrane Database Syst Rev. 2018 Apr 05;4:CD010676. doi: 10.1002/14651858.CD010676.pub2.

BACKGROUND: Panic disorder is characterised by repeated, unexpected panic attacks, which represent a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes, and in which at least four of 13 characteristic...

Cite
Bighelli I, Castellazzi M, Cipriani A, et al. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2018;4:CD010676doi: 10.1002/14651858.CD010676.pub2.
Bighelli, I., Castellazzi, M., Cipriani, A., Girlanda, F., Guaiana, G., Koesters, M., Turrini, G., Furukawa, T. A., & Barbui, C. (2018). Antidepressants versus placebo for panic disorder in adults. The Cochrane database of systematic reviews, 4CD010676. https://doi.org/10.1002/14651858.CD010676.pub2
Bighelli, Irene, et al. "Antidepressants versus placebo for panic disorder in adults." The Cochrane database of systematic reviews vol. 4 (2018): CD010676. doi: https://doi.org/10.1002/14651858.CD010676.pub2
Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, Turrini G, Furukawa TA, Barbui C. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2018 Apr 05;4:CD010676. doi: 10.1002/14651858.CD010676.pub2. PMID: 29620793; PMCID: PMC6494573.
Copy Download .nbib Format: NLM
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults.

The Cochrane database of systematic reviews

Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA.
PMID: 27730622
Cochrane Database Syst Rev. 2016 Oct 12;10:CD011170. doi: 10.1002/14651858.CD011170.pub2.

BACKGROUND: Panic disorder is common and deleterious to mental well-being. Psychological therapies and pharmacological interventions are both used as treatments for panic disorder with and without agoraphobia. However, there are no up-to-date reviews on the comparative efficacy and acceptability...

Cite
Imai H, Tajika A, Chen P, et al. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database Syst Rev. 2016;10:CD011170doi: 10.1002/14651858.CD011170.pub2.
Imai, H., Tajika, A., Chen, P., Pompoli, A., & Furukawa, T. A. (2016). Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. The Cochrane database of systematic reviews, 10CD011170. https://doi.org/10.1002/14651858.CD011170.pub2
Imai, Hissei, et al. "Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults." The Cochrane database of systematic reviews vol. 10 (2016): CD011170. doi: https://doi.org/10.1002/14651858.CD011170.pub2
Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database Syst Rev. 2016 Oct 12;10:CD011170. doi: 10.1002/14651858.CD011170.pub2. PMID: 27730622; PMCID: PMC6457876.
Copy Download .nbib Format: NLM
Tapentadol for chronic musculoskeletal pain in adults.

The Cochrane database of systematic reviews

Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J.
PMID: 26017279
Cochrane Database Syst Rev. 2015 May 27;(5):CD009923. doi: 10.1002/14651858.CD009923.pub2.

BACKGROUND: Chronic musculoskeletal pain is a prevalent condition and a major cause of disability and absence from the workplace worldwide. Opioids are frequently used to treat chronic pain, although adverse effects often restrict their long-term benefits. Tapentadol is an...

Cite
Santos J, Alarcão J, Fareleira F, et al. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;(5):CD009923doi: 10.1002/14651858.CD009923.pub2.
Santos, J., Alarcão, J., Fareleira, F., Vaz-Carneiro, A., & Costa, J. (2015). Tapentadol for chronic musculoskeletal pain in adults. The Cochrane database of systematic reviews, (5), CD009923. https://doi.org/10.1002/14651858.CD009923.pub2
Santos, João, et al. "Tapentadol for chronic musculoskeletal pain in adults." The Cochrane database of systematic reviews vol. ,5 (2015): CD009923. doi: https://doi.org/10.1002/14651858.CD009923.pub2
Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015 May 27;(5):CD009923. doi: 10.1002/14651858.CD009923.pub2. PMID: 26017279; PMCID: PMC7205027.
Copy Download .nbib Format: NLM
Agomelatine versus other antidepressive agents for major depression.

The Cochrane database of systematic reviews

Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M.
PMID: 24343836
Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851. doi: 10.1002/14651858.CD008851.pub2.

BACKGROUND: Major depressive disorder (MDD), or depression, is a syndrome characterised by a number of behavioural, cognitive and emotional features. It is most commonly associated with a sad or depressed mood, a reduced capacity to feel pleasure, feelings of...

Cite
Guaiana G, Gupta S, Chiodo D, et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;(12):CD008851doi: 10.1002/14651858.CD008851.pub2.
Guaiana, G., Gupta, S., Chiodo, D., Davies, S. J., Haederle, K., & Koesters, M. (2013). Agomelatine versus other antidepressive agents for major depression. The Cochrane database of systematic reviews, (12), CD008851. https://doi.org/10.1002/14651858.CD008851.pub2
Guaiana, Giuseppe, et al. "Agomelatine versus other antidepressive agents for major depression." The Cochrane database of systematic reviews vol. ,12 (2013): CD008851. doi: https://doi.org/10.1002/14651858.CD008851.pub2
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851. doi: 10.1002/14651858.CD008851.pub2. PMID: 24343836.
Copy Download .nbib Format: NLM
[Significance of endogenous sulfur dioxide in the regulation of cardiovascular system].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Jin HF, DU SX, Zhao X, Zhang SQ, Tian Y, Bu DF, Tang CS, DU JB.
PMID: 17657274
Beijing Da Xue Xue Bao Yi Xue Ban. 2007 Aug 18;39(4):423-5.

Since the 1980's nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide (H(2)S), the endogenous gas molecules produced from metabolic pathway, have been realized as signal molecules to be involved in the regulation of body homeostasis and to play...

Cite
Jin HF, DU SX, Zhao X, et al. [Significance of endogenous sulfur dioxide in the regulation of cardiovascular system]. Beijing Da Xue Xue Bao Yi Xue Ban. 2007;39(4):423-5
Jin, H. F., DU, S. X., Zhao, X., Zhang, S. Q., Tian, Y., Bu, D. F., Tang, C. S., & DU, J. B. (2007). [Significance of endogenous sulfur dioxide in the regulation of cardiovascular system]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 39(4), 423-5.
Jin, Hong Fang, et al. "[Significance of endogenous sulfur dioxide in the regulation of cardiovascular system]." Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences vol. 39,4 (2007): 423-5.
Jin HF, DU SX, Zhao X, Zhang SQ, Tian Y, Bu DF, Tang CS, DU JB. [Significance of endogenous sulfur dioxide in the regulation of cardiovascular system]. Beijing Da Xue Xue Bao Yi Xue Ban. 2007 Aug 18;39(4):423-5. Chinese. PMID: 17657274.
Copy Download .nbib Format: NLM
[Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification].

L'Encephale

Gruwez B, Gury C, Poirier MF, Bouvet O, Gérard A, Bourdel MC, Baylé FJ, Olié JP.
PMID: 15627047
Encephale. 2004 Sep-Oct;30(5):425-32. doi: 10.1016/s0013-7006(04)95457-7.

BACKGROUND AND AIM OF THE STUDY: Overall, the efficacy of the newer antidepressants: serotonin selective reuptake inhibitors (SSRI), selective serotonin/norepinephrine reuptake inhibitor (SNRI), noradrenergic and specific serotonergic antidepressant (NaSSA) and tianeptine is similar to that of the tricyclics, and...

Cite
Gruwez B, Gury C, Poirier MF, et al. Comparaison de deux outils de mesure des effets indésirables d'un traitement antidépresseur: la notification spontanée et l'échelle UKU. [Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification]. Encephale. 2004;30(5):425-32doi: 10.1016/s0013-7006(04)95457-7.
Gruwez, B., Gury, C., Poirier, M. F., Bouvet, O., Gérard, A., Bourdel, M. C., Baylé, F. J., & Olié, J. P. (2004). Comparaison de deux outils de mesure des effets indésirables d'un traitement antidépresseur: la notification spontanée et l'échelle UKU. [Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification]. L'Encephale, 30(5), 425-32. https://doi.org/10.1016/s0013-7006(04)95457-7
Gruwez, B, et al. "Comparaison de deux outils de mesure des effets indésirables d'un traitement antidépresseur: la notification spontanée et l'échelle UKU." [Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification]. L'Encephale vol. 30,5 (2004): 425-32. doi: https://doi.org/10.1016/s0013-7006(04)95457-7
Gruwez B, Gury C, Poirier MF, Bouvet O, Gérard A, Bourdel MC, Baylé FJ, Olié JP. Comparaison de deux outils de mesure des effets indésirables d'un traitement antidépresseur: la notification spontanée et l'échelle UKU. [Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification]. Encephale. 2004 Sep-Oct;30(5):425-32. doi: 10.1016/s0013-7006(04)95457-7. French. PMID: 15627047.
Copy Download .nbib Format: NLM
Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

CNS drugs

Carter NJ, McCormack PL.
PMID: 19480470
CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006.

Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate...

Cite
Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41doi: 10.2165/00023210-200923060-00006.
Carter, N. J., & McCormack, P. L. (2009). Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS drugs, 23(6), 523-41. https://doi.org/10.2165/00023210-200923060-00006
Carter, Natalie J, and McCormack, Paul L. "Duloxetine: a review of its use in the treatment of generalized anxiety disorder." CNS drugs vol. 23,6 (2009): 523-41. doi: https://doi.org/10.2165/00023210-200923060-00006
Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. PMID: 19480470.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 109453 entries